相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding
Hulin Jin et al.
ONCOIMMUNOLOGY (2021)
Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma
Michael T. Tetzlaff et al.
MODERN PATHOLOGY (2020)
Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
T. B. Powles et al.
ANNALS OF ONCOLOGY (2020)
Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study
Ana-Marija Grisic et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients
Ida Netterberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Maddalena Centanni et al.
CLINICAL PHARMACOKINETICS (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
Toshihiko Doi et al.
GASTRIC CANCER (2019)
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
Xin Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
Justin J. Wilkins et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions
Tong Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2017)
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
Hongshan Li et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Christopher R. Heery et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis
C. Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma
M. S. Chatterjee et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia
L. E. Friberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
